Development of Novel Therapeutics for AMKL
OBJECTIVES:
- Determine whether megakaryocyte differentiation agents comprising a Rho kinase
inhibitor and a JAK3 inhibitor can lead to proliferation arrest, polyploidization, and
terminal differentiation of blasts in specimens from patients with Down syndrome and
acute megakaryoblastic leukemia.
OUTLINE: Cryopreserved specimens are cultured and treated in vivo (in mice) and in vitro
with megakaryocytic differentiation agents comprising a Rho kinase inhibitor and a JAK3
inhibitor.
Observational
N/A
Proliferation arrest
No
John Crispino, PhD
Principal Investigator
Robert H. Lurie Cancer Center
United States: Federal Government
CDR0000671427
NCT01139307
July 2009
Name | Location |
---|